Biosimilars – Forecast – Immunology
In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this therapy area totaled approximately $4.2 billion. Throughout the 2021-2031 forecast period, increasing numbers of branded biologics in the immunology space are set to lose patent protection, and biosimilars will launch and reduce branded biologics’ patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Immunology
- Market forecast in the major pharmaceutical markets
- Major-market forecast: immune biologics
- Terminology
- Overarching forecast assumptions
- Overview of immune biological brands in forecast
- Overview of approved immune biologics
- Biosimilar entry assumptions for immune biologics
- Overview of biosimilars in immune disease assumptions
- Overview of immune biological brands in forecast
- Drug-specific forecast assumptions
- Remicade
- Outlook for Remicade
- First biosimilars of Remicade in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Remicade sales forecast for the United States: 2021-2031
- Remicade sales forecast for the EU5: 2021-2031
- Remicade sales forecast for Japan: 2021-2031
- Enbrel
- Outlook for Enbrel
- First biosimilars of Enbrel in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Enbrel sales forecast for the United States: 2021-2031
- Enbrel sales forecast for the EU5: 2021-2031
- Enbrel sales forecast for Japan: 2021-2031
- Rituxan / MabThera
- Outlook for Rituxan / MabThera
- First biosimilars of Rituxan / MabThera in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Rituxan sales forecast for the United States (immunology): 2021-2031
- MabThera sales forecast for the EU5 (immunology): 2021-2031
- Rituxan sales forecast for the United States (immunology and oncology): 2021-2031
- MabThera sales forecast for the EU5 (immunology and oncology): 2021-2031
- Humira
- Outlook for Humira
- First biosimilars of Humira in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Humira sales forecast for the United States: 2021-2031
- Humira sales forecast for the EU5: 2021-2031
- Humira sales forecast for Japan: 2021-2031
- Actemra / RoActemra
- Outlook for Actemra / RoActemra
- First biosimilars of Actemra / RoActemra in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Actemra sales forecast for the United States: 2021-2031
- RoActemra sales forecast for the EU5: 2021-2031
- Actemra sales forecast for Japan: 2021-2031
- Stelara
- Outlook for Stelara
- First biosimilars of Stelara in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Stelara sales forecast for the United States: 2021-2031
- Stelara sales forecast for the EU5: 2021-2031
- Stelara sales forecast for Japan: 2021-2031
- Cimzia
- Outlook for Cimzia
- First biosimilars of Cimzia in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Cimzia sales forecast for the United States: 2021-2031
- Cimzia sales forecast for the EU5: 2021-2031
- Cimzia sales forecast for Japan: 2021-2031
- Simponi
- Outlook for Simponi
- First biosimilars of Simponi in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Simponi sales forecast for the United States: 2021-2031
- Simponi sales forecast for the EU5: 2021-2031
- Simponi sales forecast for Japan: 2021-2031
- Orencia
- Outlook for Orencia
- First biosimilars of Orencia in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Orencia sales forecast for the United States: 2021-2031
- Orencia sales forecast for the EU5: 2021-2031
- Orencia sales forecast for Japan: 2021-2031
- Cosentyx
- Outlook for Cosentyx
- First biosimilars of Cosentyx in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Cosentyx sales forecast for the United States: 2021-2031
- Cosentyx sales forecast for the EU5: 2021-2031
- Cosentyx sales forecast for Japan: 2021-2031
- Taltz
- Outlook for Taltz
- First biosimilars of Taltz in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Taltz sales forecast for the United States: 2021-2031
- Taltz sales forecast for EU5: 2021-2031
- Taltz sales forecast for Japan: 2021-2031
- Entyvio
- Outlook for Entyvio
- First biosimilars of Entyvio in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Entyvio sales forecast for the United States: 2021-2031
- Entyvio sales forecast for the EU5: 2021-2031
- Entyvio sales forecast for Japan: 2021-2031
- Remicade
- Market forecast in the major pharmaceutical markets
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.